Neurological manifestation of leprosy

Reading File
Reading File
Finding Sources
Finding Sources
Searching PubMed

leprosy AND neurological manifestations

Searching the Web

WHO leprosy peripheral nerve impairment neurological manifestations

Reading File
Reading File
Reading Article

PMID: 39322926

Reading Article

PMID: 37850518

Reading Web Page

https://www.who.int/news-room/fact-sheets/detail/leprosy

Neurological manifestations of leprosy

Leprosy (Hansen disease), caused by Mycobacterium leprae, has a marked predilection for peripheral nerves, particularly Schwann cells. Nerve damage results from direct infection plus immune-mediated inflammation, especially during lepra reactions. It is a major cause of preventable sensory, motor, and autonomic disability.

1. Peripheral neuropathy

Typical pattern
  • Usually involves cool, superficial peripheral nerves.
  • Nerves may be thickened, tender, or both.
  • Distribution varies by type:
    • Tuberculoid leprosy: focal, asymmetric neuropathy near skin lesions.
    • Lepromatous leprosy: more diffuse, bilateral, usually symmetric polyneuropathy.
    • Pure neuritic leprosy: peripheral nerve involvement without visible skin lesions.
Commonly affected nerves are:
  • Ulnar nerve at the elbow
  • Common peroneal nerve at the fibular neck
  • Posterior tibial nerve behind the medial malleolus
  • Median nerve at the wrist
  • Radial cutaneous nerve
  • Facial nerve

2. Sensory impairment

Loss of sensation is often the earliest and most characteristic neurological feature.
  • Hypoesthesia or anesthesia over skin lesions
  • Loss of pain and temperature sensation, followed by touch and pressure sensation
  • Paresthesia, tingling, numbness, or burning neuropathic pain
  • Loss of protective sensation in hands and feet
Consequences:
  • Repeated unnoticed trauma or burns
  • Painless ulcers, especially plantar ulcers
  • Secondary infection and osteomyelitis
  • Bone resorption and deformity
A hypopigmented or erythematous patch with definite sensory loss is a WHO cardinal sign of leprosy. WHO fact sheet

3. Motor neuropathy

Motor involvement causes weakness and muscle wasting in the distribution of affected nerves.
Nerve affectedMain motor deficitResulting deformity
Ulnar nerveInterossei weakness, impaired finger abduction/adductionClawing of ring and little fingers
Median nerveThenar weakness, loss of thumb oppositionThenar wasting, thumb deformity
Common peroneal nerveLoss of ankle dorsiflexionFoot drop, high-stepping gait
Posterior tibial nerveIntrinsic foot-muscle weaknessClaw toes, unstable foot
Facial nerveWeak eye closureLagophthalmos, exposure keratitis
Radial nerveWrist extensor weaknessWrist drop, less common
Textbook examination emphasizes assessment of eye closure, finger abduction, thumb opposition, wrist extension, and ankle dorsiflexion for functional nerve impairment. Harrison's Principles of Internal Medicine, 22nd ed., section “Diagnosis.”

4. Autonomic dysfunction

Damage to autonomic fibers produces:
  • Anhidrosis or reduced sweating in affected skin
  • Dry, scaly, fissured skin
  • Loss of hair over lesions
  • Vasomotor changes
  • Dry eyes when facial/trigeminal involvement occurs
Dry, insensate skin is prone to cracks, wounds, and chronic ulceration.

5. Neuritis and lepra reactions

Neuritis is inflammation of peripheral nerves, presenting with:
  • Nerve pain and tenderness
  • New sensory loss
  • New weakness or paralysis
  • Rapid increase in nerve size
  • Sometimes edema around the nerve
It may occur:
  • At diagnosis
  • During multidrug therapy
  • After treatment completion
Silent neuritis means progressive sensory or motor loss without obvious nerve pain or tenderness. This is clinically important because irreversible paralysis can develop unnoticed.
Acute neuritis, new weakness, or recent sensory loss needs urgent specialist assessment because timely anti-inflammatory treatment can prevent permanent deficit.

6. Cranial nerve involvement

Cranial nerve involvement is less common than peripheral neuropathy. The main nerves affected are:
  • Facial nerve (VII): facial weakness and lagophthalmos
  • Trigeminal nerve (V): corneal hypoesthesia or anesthesia, impaired corneal protection, risk of corneal ulceration and blindness
  • Occasionally multiple cranial nerve palsies
A 2025 systematic review of reported cases found facial nerve involvement in 38.8% and trigeminal involvement in 28.6% of reported cranial neuropathy cases, but these figures come from selected case reports and should not be interpreted as population prevalence. Cranial-nerve review

7. Central nervous system involvement

Classically, leprosy is primarily a peripheral nervous system disease. Direct CNS involvement is rare, but case reports and limited cohorts describe:
  • Cervical myelopathy
  • Brachial plexus and spinal cord abnormalities
  • Brainstem involvement, including cranial nerve nuclei
  • Inflammatory CSF changes in rare cases
A systematic review found such CNS manifestations were uncommon and largely based on observational reports, imaging, pathology, and isolated cases. CNS systematic review

Clinical red flags

In a person with known or suspected leprosy, urgently evaluate:
  • New numbness or loss of sensation
  • New hand or foot weakness
  • Painful or tender thickened peripheral nerve
  • Foot drop, claw hand, or inability to oppose the thumb
  • Inability to close the eye fully
  • Red eye, eye pain, visual blurring, or corneal sensory loss
  • Plantar ulcer or painless recurrent injury
Summary: Leprosy neuropathy causes sensory loss, motor paralysis, autonomic skin changes, neuritis, and characteristic deformities. Peripheral nerve involvement is central to the disease, while cranial neuropathy and CNS disease are uncommon. Early recognition and treatment are key to preventing permanent disability.

Explain mononeuritis multiplex

Reading File
Finding Sources
Finding Sources
Searching PubMed

mononeuritis multiplex

Searching the Web

mononeuritis multiplex overview diagnosis causes vasculitic neuropathy

Reading File
Reading File
Reading Web Page

https://pmc.ncbi.nlm.nih.gov/articles/PMC4357592/

Mononeuritis multiplex is a pattern of peripheral neuropathy in which two or more separate, noncontiguous peripheral nerves are damaged. It is also called multiple mononeuropathy.
Unlike a length-dependent polyneuropathy, which typically causes symmetric “stocking-glove” sensory loss, mononeuritis multiplex is asymmetric, patchy, and often stepwise.

Typical clinical picture

It usually presents acutely or subacutely with:
  • Painful burning, tingling, or numbness in the territory of one nerve
  • Focal weakness and muscle wasting
  • Loss of reflexes supplied by affected nerves
  • Later involvement of another unrelated nerve, often on the opposite limb
Example: A patient may first develop a painful right foot drop from common peroneal nerve involvement, then later develop numbness and weakness of the left hand from ulnar nerve involvement.
Commonly involved nerves include:
  • Common peroneal or tibial nerves in the legs
  • Ulnar nerve in the upper limb
  • Median or radial nerves
  • Occasionally cranial nerves

Why it occurs

The classic mechanism is vasculitis of the vasa nervorum, the small blood vessels supplying peripheral nerves.
Inflammation of these vessels causes narrowing or occlusion, resulting in nerve ischemia and axonal degeneration. Therefore, vasculitic mononeuritis multiplex is characteristically painful and causes abrupt motor and sensory deficits. Goldman-Cecil Medicine, section “Vasculitic Neuropathies.”

Causes

CategoryExamples
VasculitisPolyarteritis nodosa, ANCA-associated vasculitis, eosinophilic granulomatosis with polyangiitis, rheumatoid vasculitis, cryoglobulinemic vasculitis
Connective-tissue diseaseRheumatoid arthritis, SLE, Sjögren syndrome
MetabolicDiabetes mellitus, especially diabetic radiculoplexus neuropathy
InfectionsLeprosy, HIV, hepatitis B/C, Lyme disease
Infiltrative or inflammatory disordersSarcoidosis, amyloidosis
Malignancy-relatedLymphoma, leukemic infiltration, paraneoplastic vasculitic neuropathy
Drug-relatedSome chemotherapy or immune-checkpoint-inhibitor related neuropathies
Systemic vasculitis is a leading cause. Frameworks for Internal Medicine notes that more than half of cases are due to systemic vasculitic involvement of the vasa nervorum. Frameworks for Internal Medicine, p. 610.

Relation to leprosy

Leprosy can produce a mononeuritis multiplex-like pattern, particularly in tuberculoid or borderline disease:
  • One or several peripheral nerve trunks become enlarged and impaired.
  • Deficits are often asymmetric and correspond to involved nerves.
  • Sensory loss, weakness, autonomic dysfunction, and neuropathic ulcers may develop.
  • Lepra reactions can cause acute neuritis with rapid new nerve dysfunction.
This differs from lepromatous leprosy, which more often produces a diffuse and relatively symmetric neuropathy.

Diagnosis

Diagnosis is clinical, supported by:
  1. Detailed neurological examination to map individual nerve territories.
  2. Nerve-conduction studies and electromyography: typically demonstrate an asymmetric, multifocal axonal sensorimotor neuropathy.
  3. Tests for the underlying cause, such as CBC, ESR/CRP, glucose/HbA1c, renal/liver function, ANA, ANCA, rheumatoid factor, complement, hepatitis and HIV testing, and tests directed by clinical suspicion.
  4. Nerve with or without muscle biopsy if vasculitic neuropathy is strongly suspected and diagnosis remains uncertain.

Management principle

Mononeuritis multiplex is a neurological syndrome, not a diagnosis by itself. Treatment targets the cause:
  • Vasculitic neuropathy: urgent specialist-directed immunosuppression, commonly glucocorticoids with additional agents for severe disease.
  • Diabetes: glycemic management plus pain control and rehabilitation.
  • Leprosy: multidrug therapy; acute neuritis or lepra reaction may require prompt anti-inflammatory treatment under specialist supervision.
  • Infection or malignancy: cause-specific treatment.
Urgent assessment is needed for rapidly evolving weakness, foot drop, inability to use a hand, severe neuropathic pain, or eye-closing weakness, since timely therapy may limit permanent nerve loss.
This is a shared conversation. Sign in to Orris to start your own chat.